Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03949478

Treating Postictal Symptoms Using Ibuprofen and Nifedipine

An Initial Clinical Study to Treat Postictal Symptoms

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
University of Calgary · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the effect of ibuprofen or nifedipine on post-seizure hypoperfusion and neurological deficits in patients with epilepsy. One group will receive ibuprofen, another will receive nifedipine, and anther placebo.

Detailed description

Immediately following seizures, brain blood flow is significantly reduced for approximately one hour and is located to the brain area where the seizure originated. This may contribute to symptoms that patients experience immediately following seizures and in between seizures. Animal studies have shown that that giving anti-inflammatory drugs (e.g., ibuprofen) and blood pressure medications (e.g., nifedipine) prevents the hypoperfusion and behavioural impairments seen in animals immediately following seizures. Thus, two classes of inexpensive and well-tolerated drugs - already in clinical use - have been identified that can be tested in humans to prevent the serious consequences that follow seizures. The investigators will study 90 subjects admitted to hospital for epilepsy investigations. The investigators will randomly divide the patients into three treatment groups (30 patients each). Patients will receive either placebo, ibuprofen, or nifedipine while in hospital. The effect of each of these treatments on the severity of hypoperfusion and neurological deficits that follows seizures will then be assessed.

Conditions

Interventions

TypeNameDescription
DRUGIbuprofenIbuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
DRUGNifedipineNifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
DRUGPlaceboSugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.

Timeline

Start date
2021-02-01
Primary completion
2025-01-01
Completion
2025-03-01
First posted
2019-05-14
Last updated
2024-05-09

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT03949478. Inclusion in this directory is not an endorsement.